Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Qingcai Meng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7433-3121; OpenAlex author ID A5100754441. Sources: OpenAlex.

Their work

Papers
69 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 5 papers · 2018: 7 papers · 2019: 6 papers · 2020: 9 papers · 2021: 12 papers · 2022: 5 papers · 2023: 10 papers · 2024: 7 papers · 2025: 4 papers · 2026: 2 papers

Papers 50 of 69

  1. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  2. ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.09.032↗
  3. The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. Co-author DOI 10.1016/j.tranon.2025.102346↗
  4. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  5. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  6. Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030. Co-author DOI 10.3389/fonc.2025.1660313↗
  7. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  8. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ebiom.2024.105098↗
  9. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Co-author DOI 10.1016/j.redox.2024.103200↗
  10. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.019↗
  11. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  12. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. Co-author DOI 10.1186/s12885-024-11842-5↗
  13. Identifying the risk factors for pancreatic fistula after laparoscopic pancreaticoduodenectomy in patients with pancreatic cancer. First author DOI 10.4240/wjgs.v16.i6.1609↗
  14. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.03.037↗
  15. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Co-author DOI 10.1016/j.csbj.2023.04.003↗
  16. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… Co-author DOI 10.1016/j.tranon.2023.101692↗
  17. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  18. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  19. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… Co-author DOI 10.1186/s13063-023-07456-0↗
  20. Reappraisal of Tumor Deposit as a Prognostic Factor in Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13102-5↗
  21. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… Co-author DOI 10.3390/curroncol30030228↗
  22. Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Can… Co-author DOI 10.3390/ijms24043270↗
  23. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. Co-author DOI 10.3390/ijms24043476↗
  24. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… Co-author DOI 10.1016/j.csbj.2022.07.029↗
  25. Pyroptosis-related lncRNA pairs to estimate the molecular features and prognostic outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101524↗
  26. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Co-author DOI 10.1038/s41388-022-02306-w↗
  27. Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09863-z↗
  28. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12920-022-01371-0↗
  29. Emerging roles of the solute carrier family in pancreatic cancer. Co-author DOI 10.1002/ctm2.356↗
  30. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-021-03866-y↗
  31. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  32. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Co-author DOI 10.1186/s12943-021-01400-z↗
  33. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic rev… First author DOI 10.21037/gs-21-16↗
  34. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer First author DOI 10.21203/rs.3.rs-733520/v1↗
  35. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  36. Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. Co-author DOI 10.3389/fonc.2021.640820↗
  37. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.643465↗
  38. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Co-author DOI 10.3390/ijms222010944↗
  39. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. Co-author DOI 10.7150/ijbs.59117↗
  40. Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. Co-author DOI 10.7150/thno.56174↗
  41. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Co-author DOI 10.1080/15548627.2019.1628540↗
  42. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002998↗
  43. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317163↗
  44. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Co-author DOI 10.1186/s12943-020-01167-9↗
  45. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Co-author DOI 10.18632/aging.104134↗
  46. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.18632/aging.202199↗
  47. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. Co-author DOI 10.21037/atm-20-2554a↗
  48. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Co-author DOI 10.7150/thno.40566↗
  49. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.9602↗
  50. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002668↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 63 shared papers, 2017–2026 · strength 8.63
  2. Jie Hua · 55 shared papers, 2018–2026 · strength 7.88
  3. Si Shi · 57 shared papers, 2017–2026 · strength 7.38
  4. Jin Xu · 52 shared papers, 2017–2026 · strength 6.61
  5. Chen Liang · 51 shared papers, 2017–2026 · strength 6.57
  6. Wei Wang · 25 shared papers, 2021–2026 · strength 4.16
  7. Bo Zhang · 19 shared papers, 2017–2024 · strength 2.88
  8. Miaoyan Wei · 15 shared papers, 2019–2026 · strength 2.27
  9. Rong Tang · 14 shared papers, 2020–2025 · strength 2.22
  10. Zhen Tan · 11 shared papers, 2020–2026 · strength 1.80
  11. Zeyin Rong · 7 shared papers, 2021–2026 · strength 1.32
  12. Yiyin Zhang · 11 shared papers, 2018–2023 · strength 1.21
  13. Quanxing Ni · 14 shared papers, 2017–2020 · strength 1.13
  14. Xiaomeng Liu · 7 shared papers, 2019–2025 · strength 0.99
  15. Jianhui Yang · 4 shared papers, 2021–2026 · strength 0.84
  16. Dingkong Liang · 11 shared papers, 2017–2019 · strength 0.83
  17. Jiang Liu · 7 shared papers, 2019–2021 · strength 0.78
  18. Siyuan Lu · 5 shared papers, 2022–2023 · strength 0.77
  19. Jin Xu · 4 shared papers, 2022–2026 · strength 0.74
  20. Mingming Xiao · 3 shared papers, 2024–2026 · strength 0.66
  21. Mingwei Dong · 3 shared papers, 2023–2026 · strength 0.62
  22. Yi Qin · 8 shared papers, 2017–2020 · strength 0.60
  23. Shunrong Ji · 8 shared papers, 2017–2020 · strength 0.59
  24. Yuan Liu · 3 shared papers, 2023–2024 · strength 0.57
  25. Qiong Du · 3 shared papers, 2023–2025 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.